Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Grows By 148.1%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 99,000 shares, an increase of 148.1% from the November 15th total of 39,900 shares. Based on an average trading volume of 90,700 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.3% of the company’s shares are sold short.

SAB Biotherapeutics Trading Up 5.4 %

Shares of SABS stock traded up $0.21 during trading hours on Friday, hitting $4.08. 31,140 shares of the company were exchanged, compared to its average volume of 35,255. SAB Biotherapeutics has a fifty-two week low of $2.16 and a fifty-two week high of $8.40. The company has a 50 day simple moving average of $3.14 and a two-hundred day simple moving average of $2.92. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. On average, research analysts forecast that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SABS has been the subject of several analyst reports. Chardan Capital restated a “buy” rating and set a $25.00 price target on shares of SAB Biotherapeutics in a report on Thursday, November 7th. Oppenheimer reiterated an “outperform” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a research report on Thursday, September 12th. Finally, Craig Hallum began coverage on shares of SAB Biotherapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.40.

Hedge Funds Weigh In On SAB Biotherapeutics

An institutional investor recently bought a new position in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC bought a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned approximately 0.21% of SAB Biotherapeutics at the end of the most recent reporting period. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.